ClinicalTrials.gg
CompletedNCT01599507Updated Mar 3, 2014

Study of FG-4592 in Subjects With Chronic Kidney Disease in China

A Phase 2 interventional study of FG-4592 and Placebo in Anemia in Chronic Kidney Disease, sponsored by FibroGen. Completed at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-03-03.

Sponsored by FibroGen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
91
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
31st of 43
91 · median 154
Started
2011
with 2 others
Phase 2
8 of 43
none open now
Registered
7th of 43
by date
Lead sponsor
20 of 43
FibroGen

Among the 43 studies testing roxadustat in Anemia, this one is the 31st largest by enrollment, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 7th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of anemia in non-dialysis chronic kidney disease patients.

Read the detailed description

Dose ranging study with two consecutive dose escalation cohorts. The study objective is to demonstrate that FG-4592 is effective in the correction of anemia in chronic kidney disease patients.

03

Conditions studied

  • Anemia in Chronic Kidney Disease

Browse trials for

Keywords

  • Anemia
  • Renal
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years
  2. Subject has voluntarily signed and dated an form
  3. Chronic Kidney Disease, not receiving dialysis
  4. (Hb) values in 4 screening visits and the mean Hb must be \<10g/dL
  5. Aminotransferase levels ( [ALT], aspartate aminotransferase [AST]) and total must be ≤ (ULN) during the screening period
  6. Serum alkaline phosphatase (ALP) ≤2x ULN during screening period. Subjects with serum ALP values between 1 x and 2 x ULN may be included only if bone-specific ALP (BSAP) is also elevated > ULN
  7. Total bilirubin values must be ≤ULN during screening period
  8. Serum folate and vitamin B12 levels above the lower limit of normal (LLN)
  9. Body weight: 40 to 100 kg (dry weight) inclusive
  10. (BMI): 16 to 38 kg/m2 inclusive

Exclusion criteria

Exclusion Criteria:

  1. Received any erythropoiesis-stimulating agent (ESA) other than epoetin alfa within 12 weeks prior to Day 1
  2. Any infection or evidence of an underlying infection such as a white blood cell count (WBC) > during screening on two separate occasions,
  3. Positive for any of the following: (HIV); surface antigen (HBsAg); anti- virus antibody (anti-HCV Ab)
  4. History of chronic liver disease
  5. Class III or IV congestive heart failure
  6. Chronic inflammatory disease other than glomerulonephritis that could impact erythropoiesis (e.g., systemic lupus erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in remission
  7. Active or chronic gastrointestinal bleeding, or a known coagulation disorder
  8. Hemoglobinopathy (e.g., homozygous sickle-cell disease, thalassemia of all types, etc.)
  9. Hematological disorders, including myelodysplastic syndrome, multiple myeloma, or pure red cell aplasia
  10. History of hemosiderosis, hemochromatosis, polycystic kidney disease, or anephric
  11. Active hemolysis or diagnosis of hemolytic syndrome
  12. Known bone marrow fibrosis
  13. Uncontrolled or symptomatic secondary hyperparathyroidism (PTH>600ng/L)
  14. Any prior organ transplantation
  15. Drug-treated gastroparesis, short-bowel syndrome, or any other gastrointestinal condition that may lead to reduced absorption of study drug
  16. Serum albumin \<3 g/dL
  17. History of alcohol or drug abuse; or a positive drug screen for a substance that has not been prescribed for the subject
  18. Prior treatment with FG-4592
  19. Use of an medication or treatment, or carryover effect of an investigational treatment expected, during the screening visit, treatment and follow-up period.
  20. Use of traditional Chinese medicines (TCM) during the screening visit to Day 1 or plans to use TCM during the study unless approved in advance by the Medical Monitor
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    FG-4592

    Active Drug

    Drug: FG-4592

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • TIW dosing, capsule

  • DrugPlacebo

    TIW dosing, capsule

06

What researchers measure

Primary outcomes

  1. Maximum change in hemoglobin by Week 9 from baseline

    Time frame: Week 9

Secondary outcomes

  1. Proportion of subjects achieving a target Hb level ≥11 g/dL by Weeks 5,6,7,8 and 9.

    Time frame: Week 9

  2. Proportion of subjects with a Hb increase from baseline ≥1.0 g/dL.

    Time frame: Week 9

07

Study locations

13 sites
  • Peking Union Medical College Hospital
    Beijing, China
  • Peking University First Hospital
    Beijing, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • West China Hospital
    Chengdu, China
  • First affiliated hospital of Dalian medical university
    DaLian, China
  • First Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, China
  • Zhejiang University No 1. Hospital
    Hangzhou, China
  • Chang Zheng Hospital
    Shanghai, China
  • Huashan Hospital
    Shanghai, China
  • Renji Hospital
    Shanghai, China
  • RuiJin Hospital
    Shanghai, China
  • XinHua Hospital
    Shanghai, China
  • Shenzhen People's Hospital
    Shenzhen, China
08

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2012
First posted
May 16, 2012
Start
Dec 2011
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Last update
Mar 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01599507
Lead sponsor
FibroGen
Responsible party
Sponsor
First posted
May 16, 2012
Start date
Dec 2011
Primary completion
Jan 2013
Completion
Jan 2013
Last update
Mar 3, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion